

The RAS targeting therapies market is anticipated to grow at an annualized rate of over 50%, by Roots Analysis

The RAS targeting therapies market is anticipated to grow at an annualized rate of over 50%, by Roots Analysis

LONDON, ENGLAND, UNITED KINGDOM, October 12, 2021

/EINPresswire.com/ -- Given that conventional therapies have been unable to exhibit significant efficacy in the treatment of RAS mutated cancers, novel drugs, specifically targeting the RAS gene, have emerged as a promising alternative, supported by extensive research

[Roots Analysis](#) has announced the addition of “[RAS Targeting Therapies Market, 2021-2031](#)” report to its list of offerings.

Growing research activity in the RAS targeting domain has resulted in a surge in the interest of biopharmaceutical developers in this rapidly evolving sector. These therapies are being developed against specific oncogenic RAS mutations that are believed to be responsible for close to 30% of the overall human cancers. Moreover, the first and only approved RAS targeted therapy, named LUMAKRASTM, has provided a boost to this market, by providing a treatment for a previously deemed undruggable target.

To order this 140+ page report, which features 95+ figures, please visit <https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html>

Example highlights

RAS Targeting Therapies: Market Landscape
Distribution by Phase of Development

RAS Targeting Therapies: Market Landscape
Distribution by Route of Administration

RAS Targeting Therapies: Market Landscape
Distribution by Line of Treatment and Type of Therapy^{1,2}

Insightful graphical summaries, offering diverse perspectives concerning the current product pipeline based on several relevant parameters

Executive Insight
Chief Executive Officer, an Israeli-based Organization
Our product is a first-of-its-kind* molecule in clinical development that directly targets KRAS. It is worth mentioning that none of the inhibitors have been effectively developed to silence KRAS, till date. Specifically, monoclonal antibodies cannot be used to target this mutation as the target is located within the cell. We further observed that targeting KRAS using RNAi is very effective and extremely potent. However, for the treatment of pancreatic cancer, we are still focused on developing therapies targeting KRAS.

Excerpts of conversations, featuring relevant insights on the current status and likely evolution of market, with representatives from key stakeholder companies

2021 © Roots Analysis

Example highlights

List of RAS Targeting Therapies

| S. No. | Developer Name | Drug Name | Current Status | Drug Class | Type of Therapy | Target Gene | Route of Administration | Line of Treatment | Target Indication | Trial ID |
|--------|----------------|----------------------|----------------|------------------------|-----------------|-------------|-------------------------|---------------------------------|----------------------------|-------------|
| 1 | AMGEN | LUMAKRAS™ | Approved | Small Molecule | Monotherapy | KRAS | Oral | 2 nd line of therapy | Non-Small Cell Lung Cancer | NCT04303780 |
| 8 | targovax | TG01 | Phase II | Peptide Cancer Vaccine | | | | | | |
| 22 | humanigen | Lenzilumab | Phase II | Monoclonal Antibody | | | | | | |
| 38 | moderna | mRNA-5675/V941 | Phase I | Oligonucleotide | | | | | | |
| 86 | Nucleon | KRAS-siRNA NP | Preclinical | Oligonucleotide | | | | | | |
| 105 | Aro | ABX300 | Preclinical | Oligonucleotide | | | | | | |
| 124 | JALIEF | KRAS Protein Vaccine | Preclinical | Peptide Cancer Vaccine | | | | | | |
| 148 | osprey | SO2-AAC-KRAS | Discovery | Cell Therapy | | | | | | |
| 153 | HIMAB | HBI-2376 | Discovery | Small Molecule | | | | | | |

Information on 85+ unique and novel therapy candidates targeting RAS (KRAS / HRAS / NRAS) gene is available in the detailed report

Note 1: Analysis includes therapies for which information on the aforementioned parameters was available.
Note 2: Other indications for which RAS targeting therapies are being investigated include Breast cancer, COVID-19, Glioblastoma, Multiple Myeloma, Ovarian cancer, Phelan-McDermid syndrome, Prostate cancer and Rectal cancer

2021 © Roots Analysis

RAS Targeting Therapies by Target Indication

Example highlights

Key Market Insights

More than 155 drug candidates targeting the RAS gene are currently being investigated

Over 70% of the therapies are being evaluated across preclinical and clinical stages, either as monotherapies or in combination with other products. Majority of the RAS targeting therapies (79%) are designed for administration via the oral route.

22,000+ patients have been enrolled in over 120 clinical trials, worldwide Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 5%, in the past three years. Of the total number of trials, close to 25% of the studies have already been completed, while 60% are active and still recruiting patients.


Close to 300 articles focused on RAS mutated colorectal cancer have been published

Several industry, as well as non-industry, players engaged in this

domain are undertaking numerous initiatives to identify and develop novel RAS targeting therapies. Majority of the authors affiliated to deemed universities have published articles focused on KRAS (80%), in last one year.

Partnership activity has grown at an annualized rate of nearly 10%, between 2017 and 2020 Maximum number of partnerships were observed to be inked in 2019, indicating a recent rise in the interest of stakeholders in this domain. Majority of the deals were reported to be product licensing agreements, representing over 30% of the total number of instances.

Over USD 1,500 million has been invested by both private and public investors, since 2016 Of the total, close to USD 600 million was raised through venture capital financing, representing around 40% of the overall share. On the other hand, over 5 instances of IPOs / secondary offerings were reported, wherein players collectively raised more than USD 775 million in financing.



North America and Europe anticipated to capture over 90% of market share by 2031
Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the growing demand for targeted therapeutic modalities. It is worth mentioning that small molecules currently represent a significant share of the overall market, and this trend is unlikely to change in the foreseen future.

To request a sample copy / brochure of this report, please visit
<https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html>

Key Questions Answered

- Which are the key candidates being developed across preclinical and clinical stages of development?
- What are the key therapeutic indications for which RAS targeting therapies are being investigated?
- What are the key challenges faced by stakeholders engaged in this domain?
- Who are the leading industry and non-industry players engaged in the development of RAS targeting therapies?
- What are the key geographies where research focused on RAS mutated cancer is being conducted?
- Who are the key investors in this domain?
- What kind of partnership models are commonly adopted by industry stakeholders?
- What are the key value drivers that are likely to influence the evolution of this upcoming market?
- How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity associated with the RAS [targeting therapies market](#) has been analyzed across the following segments:

- Target Indication
 - Acute Myeloid Leukemia
 - Colorectal cancer
 - Head and Neck cancer
 - Lung cancer
 - Ovarian cancer
 - Pancreatic cancer
 - Phelan-Mcdermid Syndrome
 - Skin cancer

- Type of Molecule
 - Biologic
 - Small Molecule

- Type of Therapy
- Monotherapy
- Combination Therapy

- Route of Administration
- Intravenous
- Intradermal
- Oral

- Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World

The research includes detailed profiles of 85+ drugs being developed by key players (listed below); each profile further features an overview of the developer, details related to its financials (if available), recent developments, and an informed future outlook.

- Amgen
- AstraZeneca
- BridgeBio
- Boehringer Ingelheim
- Jacobio Pharmaceuticals
- Mirati Therapeutics
- Moderna
- Novartis
- Onconova Therapeutics
- Revolution Medicine
- Targovax
- Verastem Oncology

For additional details, please visit

<https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html> or email sales@rootsanalysis.com

You may also be interested in the following titles:

1. Squamous Non-Small Cell Lung Cancer Market, 2021-2031
2. Novel T-Cell Immunotherapies Market, 2021-2030
3. HER2 Targeting Therapies Market, 2021-2030

Contact:
Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

Gaurav Chaudhary

Roots Analysis

+1 415-800-3415

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/553629354>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.